

Enquiries: CPA Ref: HP16-2024EPI e-mail: cpapharma@health.gov.za

Cover Page for Contractual Price Adjustments for HP16-2024EPI

CPA Period: 1.0

Active: 1 August 2024

Rates of Exchange: 6/3 Month

Currency	Base Average Rates of Exchange Average for the period 01 January 2022 to 30 June 2022	Previous CPA 0.1 Adjustment Rate (3 Month)	Period for calculating adjustment Rate of Exchange	Current CPA 1.0 Adjustment Rate (6 Month)	Current CPA 1.0 Adjustment Rate (3 Month)
Yuan	R2.38	R2.63		R2.60	R2.56
Indian Rupee	R0.20	R0.23	01 January 2024 to 30 June 2024	R0.23	R0.22
Euro	R16.85	R20.50		R20.26	R20.00
BR Pound	R20.01	R23.95		R23.70	R23.44
Danish Krone	R2.26	R2.75		R2.72	R2.68
US Dollar	R15.40	R18.89		R18.73	R18.58

This Price Adjustment is reflected on Addendum 10 to 13 for HP16-2024EPI.

Yours faithfully

K JAMALOODIEN

& Janaroo Tren

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT



Enquiries: CPA Ref: HP16-2024EPI e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP16-2024EPI: SUPPLY AND DELIVERY OF VACCINES USED IN THE EXPANDED PROGRAMME ON IMMUNISATION (EPI) OF THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JANUARY 2024 TO 31 DECEMBER 2026

ADDENDUM 10: CIPLA MEDPRO MANUFACTURING (PTY) LTD- PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following Cipla Medpro Manufacturing (Pty) Ltd prices, effective 1 August 2024.

Item No	Description	NSN	Current Price	Revised Price
5	Vaccine, conjugated, pneumococcal, multivalent, containing a of minimum 8 pneumococcal serotypes that includes 1, 5, 6B, 7F, 9V, 14, 19F and 23F in a single dose vial or pre-filled syringe. For intramuscular administration.	222001550	R115.32	R113.70
10	Vaccine, hepatitis B, containing purified hepatitis B surface antigen (HBsAG) in strength of 10mcg / 0.5ml per dose, 10 multidose vial (100mcg/5ml), for paediatric use. For intramuscular administration.	180323312	R115.81	R114.24

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Yours faithfully

MS K JAMALOODIEN

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT

anasooden



Enquiries: CPA Ref: HP16-2024EPI e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP16-2024EPI: SUPPLY AND DELIVERY OF VACCINES USED IN THE EXPANDED PROGRAMME ON IMMUNISATION (EPI) OF THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JANUARY 2024 TO 31 DECEMBER 2026

ADDENDUM 11: GLAXOSMITHKLINE SA (PTY) LTD- PRICE ADJUSTMENT

The Department has activated the right to price reduction due to favourable changes in foreign exchange. Please amend your records for the following GlaxoSmithKline SA (Pty) Ltd prices, effective 1 August 2024.

Item	Description	NSN	Current	Revised
No	Description	NON	Price	Price
6	Vaccine, rotavirus, containing the following as a minimum per vial, live attenuated human fully liquid in a pre-filled tube or plastic vial rotavirus strain not less than 106 CCID50 per dose. For oral administration.	181810302	R131.48	R128.88
9	Vaccine, human papilloma virus, multivalent, containing the following serotypes as a minimum: Type 16 and Type 18, single or multidose vial or pre-filled syringe. For intramuscular administration.	222001064	R393.82	R386.03

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Yours faithfully

MS K JAMALOODIEN

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT



Enquiries: CPA Ref: HP16-2024EPI e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP16-2024EPI: SUPPLY AND DELIVERY OF VACCINES USED IN THE EXPANDED PROGRAMME ON IMMUNISATION (EPI) OF THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JANUARY 2024 TO 31 DECEMBER 2026

ADDENDUM 12: SANOFI-AVENTIS SA (PTY) LTD- PRICE ADJUSTMENT

Please amend your records for the following Sanofi-Aventis SA (Pty) Ltd price, effective 1 August 2024.

Item No	Description	NSN	Current Price	Revised Price
14	Vaccine, combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) per 0.5ml dose, single or multidose vial or pre-filled syringe presentation. For intramuscular administration.	181756185	R158.22	R158.44

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Yours faithfully

MS K JAMALOODIEN

of Janaroo Sien

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT



Enquiries: CPA Ref: HP16-2024EPI e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP16-2024EPI: SUPPLY AND DELIVERY OF VACCINES USED IN THE EXPANDED PROGRAMME ON IMMUNISATION (EPI) OF THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JANUARY 2024 TO 31 DECEMBER 2026

ADDENDUM 13: THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA (PTY) LTD- PRICE ADJUSTMENT

Please amend your records for the following The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd prices, effective 1 August 2024.

Item No	Description	NSN	Current Price	Revised Price
1	Vaccine, BCG (Bacillus Calmette-Guérin), containing 0.75 mg per 1 ml of live attenuated Mycobacterium Bovis, multi dose of at least 20 doses vial plus diluent if applicable. For intradermal administration. With Vaccine Vial Monitor.	180327653	R158.66	R159.18
15	Vaccine, tetanus toxoid, containing 40IU of purified tetanus toxoid per 0.5ml, 10 dose vial. For intramuscular administration (Use in A&E only)	181760445	R49.36	R49.40

In the event that an incorrect price adjustment was made during the calculation of the contract price adjustment, the Department of Health reserves the right to adjust the price in accordance with the correct calculation.

Foreign exchange adjustments may not result in a price exceeding the current Single Exit Price.

Yours faithfully

MS K JAMALOODIEN

CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT